Distributor inventory | Tablet
Cabergoline 0.5 mg (per tablet)
Treatment of hyperprolactinemia (raised prolactin levels) due to prolactin-secreting pituitary adenoma (prolactinoma) or other causes; management of symptoms such as galactorrhea, amenorrhea/irregular periods, infertility, decreased libido; may be used for suppression of lactation when prescribed.
Cabergoline is a long-acting dopamine D2 receptor agonist. It inhibits prolactin secretion from the pituitary gland, thereby lowering serum prolactin levels and reducing prolactin-related symptoms.
Take by mouth exactly as prescribed, preferably with food to reduce nausea. Often started at a low dose (commonly 0.25 mg twice weekly) and adjusted based on prolactin levels and clinical response; swallow tablet with water. Do not stop abruptly without medical advice; periodic blood tests and follow-up may be required.
Common side effects of CABERNORM TAB may include:
Use only under specialist supervision. May cause dizziness/sleepiness—avoid driving if affected. Risk of low blood pressure, especially at start of therapy; rise slowly from sitting/lying. Long-term/high-dose use has been associated with heart valve disease and fibrotic reactions—doctor may advise baseline and periodic echocardiography and monitoring for breathlessness/chest pain/swelling. Use with caution in patients with cardiovascular disease, uncontrolled hypertension, psychiatric illness, history of fibrotic disorders, or liver impairment. Not recommended in uncontrolled hypertension or history of valvular heart disease unless advised. Seek medical help for severe headache/visual changes or symptoms suggestive of impulse control disorders.
